Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial -

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Musculo-skeletal disorders
Summary
RCT (n=449) reported that more patients achieved the primary endpoint of ACR20 versus placebo at 12 weeks (filgotinib 200 mg, 66.0%, 100 mg, 57.5%, placebo 31.1%; difference vs placebo: 34.9% and 26.4%, respectively; both p>0.001).
UKMi comment
A related editorial discusses the implications of these short term results noting that although having more viable treatment options for RA refractory to biologic DMARDs is desirable, to help promote use, these oral JAK inhibitor therapies will need to be priced at levels comparable with the conventional synthetic DMARDs rather than the biologics.
Related links: Editorial